Cite
HARVARD Citation
Mease, P. et al. (n.d.). THU0420 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. Annals of the rheumatic diseases. p. 341. [Online].